Prospective audit of post-chemotherapy febrile neutropenia in patients with solid cancer and lymphoma in two Singaporean cancer centres

Annals of the Academy of Medicine Singapore

Volumn 41, Issue 7, 2012, Pages 287-293

  Wong, Mabel ^a   Jin, Jing ^b   Tan, Min Han ^a   Lee, Yee Mei ^c   Lee, Ten Eng ^d   Ding, Ying ^d   Yong, Hong Chan ^d   Lim, Siew Eng ^c   Chai, Louis Ya ^d   Chau, Noan Minh ^a   Hsu, Li Yang ^d  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b Centre for Health Services Research   (Singapore)

^c Cancer Science Institute of Singapore   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Carbapenems; MASCC score; Outpatient management; Vancomycin

Indexed keywords

ANTIFUNGAL AGENT; CARBAPENEM; GRANULOCYTE COLONY STIMULATING FACTOR; PYRROLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; ANAEROBE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG USE; FEBRILE NEUTROPENIA; FEMALE; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LENGTH OF STAY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT CARE; PROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SINGAPORE; SKIN FLORA; SOLID TUMOR; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84865631827     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Au E, Ang PT. Management of chemotherapy-induced neutropenic sepsis - combination of cephalosporin and aminoglycoside. Ann Acad Med Singapore 1993;22:319-322.
2. Wong GC, Tan BH. Use of antibiotics in a haematology ward - an audit. Ann Acad Med Singapore 2008;37:21-26.
3. Jin J, Lee YM, Ding Y, Koh LP, Lim SE, Lim R, et al. Prospective audit of febrile neutropenia management at a tertiary university hospital in Singapore. Ann Acad Med Singapore 2010;39:453-459.
4. Viscoli C. Infectious complications in neutropenic cancer patients. Available at: http://cme.medscape.com/viewarticle/468938 Accessed 20 December 2010.
5. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66.
6. Carstensen M, Sorensen JB. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol 2008;6:199-208.
7. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.
8. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Defi nitions Conference. Crit Care Med 2003;31:1250-1256.
9. De Pauw B, Walsh TH, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
10. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
11. Zeger SL, Liang K Y, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-1060.
12. Johnson TN, DeJesus YA, McMahon L, Rolston KV, Row MB. Outpatient management of febrile neutropenia: is it safe yet? J Support Oncol 2008;6:219-220.
13. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005;5:431-439.
14. Aapro MS, Bohlius J, Cameron DA, Lago LD, Donnelly JP, Kearney N, et al. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32.
15. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205.
16. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198-4214.